Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease

29 May 2019

Abstract excerpt

γ promoter by demonstrating that adipocyte-specific knockout of EZH2, a member of the PRC2, prevents adipocyte reprogramming and reverses bone changes in a mouse model. We validated the strong correlation between the frequency of bone lesions and the expression of EZH2 in marrow adipocytes from patients in remission. These results define a role for adipocytes in genesis of myeloma-associated bone disease and that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone health and treatments
Share to Hematological disorders and diagnostics
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31142679
DOI: 10.1126/scitranslmed.aau9087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Reprogrammed marrow adipocytes contribute to myeloma-induced bone diseasePMID 31142679Read ↗

EZH2 serves as a viable therapeutic target for myeloma-induced osteolytic bone destructionSemantic proximity Read ↗

Epigenetic‐Based Mechanisms of Osteoblast Suppression in Multiple Myeloma Bone DiseaseSemantic proximity Read ↗

Myeloma-Modified Adipocytes Exhibit Metabolic Dysfunction and a Senescence-Associated Secretory Phenotype.Semantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

Hypoxia/HIF Signaling Negatively Regulates Bone Marrow Adiposity after Radiation ExposureSemantic proximity Read ↗

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma–Induced Epigenetic Suppression of Osteoblast DifferentiationSemantic proximity Read ↗

Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone diseaseSemantic proximity Read ↗

Molecular Deconvolution of Bone Marrow Adipose Tissue Interactions with Malignant Hematopoiesis: Potential for New Therapy DevelopmentSemantic proximity Read ↗

Osteoblast suppression in multiple myeloma bone diseaseSemantic proximity Read ↗

Histone methylation regulator PTIP is required to maintain normal and leukemic bone marrow nichesSemantic proximity Read ↗

Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone diseaseSemantic proximity Read ↗

Ezh2 mediates epigenetic regulation of osteoclastogenesis and bone remodeling in miceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.